Show simple item record

dc.contributor.authorGore, M
dc.contributor.authorSzczylik, C
dc.contributor.authorPorta, C
dc.contributor.authorBracarda, S
dc.contributor.authorBjarnason, G
dc.contributor.authorOudard, S
dc.contributor.authorLee, S
dc.contributor.authorHaanen, J
dc.contributor.authorCastellano, D
dc.contributor.authorVrdoljak, E
dc.contributor.authorSchöffski, P
dc.contributor.authorMainwaring, P
dc.contributor.authorHawkins, Robert E
dc.contributor.authorCrinò, L
dc.contributor.authorKim, T
dc.contributor.authorCarteni, G
dc.contributor.authorEberhardt, W
dc.contributor.authorZhang, K
dc.contributor.authorFly, K
dc.contributor.authorMatczak, E
dc.contributor.authorLechuga, M
dc.contributor.authorHariharan, S
dc.contributor.authorBukowski, R
dc.date.accessioned2015-07-30T08:57:27Zen
dc.date.available2015-07-30T08:57:27Zen
dc.date.issued2015-06-30en
dc.identifier.citationFinal results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma. 2015, 113 (1):12-9 Br J Canceren
dc.identifier.issn1532-1827en
dc.identifier.pmid26086878en
dc.identifier.doi10.1038/bjc.2015.196en
dc.identifier.urihttp://hdl.handle.net/10541/561255en
dc.description.abstractWe report final results with extended follow-up from a global, expanded-access trial that pre-regulatory approval provided sunitinib to metastatic renal cell carcinoma (mRCC) patients, ineligible for registration-directed trials.
dc.language.isoenen
dc.rightsArchived with thanks to British journal of canceren
dc.titleFinal results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma.en
dc.typeArticleen
dc.identifier.journalBritish Journal of Canceren
html.description.abstractWe report final results with extended follow-up from a global, expanded-access trial that pre-regulatory approval provided sunitinib to metastatic renal cell carcinoma (mRCC) patients, ineligible for registration-directed trials.


This item appears in the following Collection(s)

Show simple item record